The prevention of tardive dyskinesia
Abstract
The publication of numerous articles on tardive dyskinesia has had little effect on the excessive use of neurolepic drugs in psychiatric populations. If current prescribing patterns are not drastically changed, larger numbers of patients will be afflicted by conspicuous, sometimes disabling neurological side effects. The risk of permanent neurological disorder can be minimized by monitoring side effects and systematically reducing drug doses in hospitals, outpatient centers, and private practice. However, one should not underestimate the difficulty in implementing such a program in facilities that rely heavily on chemotherapy.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
